CINECA IRIS Institutional Research Information System

BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.

Enzalutamide in metastatic prostate cancer before chemotherapy.

Giorgio Scagliotti
Membro del Collaboration Group
2014-01-01

Abstract

BACKGROUND Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.
2014
371
424
433
Beer TM;Armstrong AJ;Rathkopf DE;Loriot Y;Sternberg CN;Higano CS;Iversen P;Bhattacharya S;Carles J;Chowdhury S;Davis ID;de Bono JS;Evans CP;Fizazi K;Joshua AM;Kim CS;Kimura G;Mainwaring P;Mansbach H;Miller K;Noonberg SB;Perabo F;Phung D;Saad F;Scher HI;Taplin ME;Venner PM;Tombal B;PREVAIL Investigators; Giorgio Scagliotti
03A-Articolo su Rivista
File in questo prodotto:
File Dimensione Formato  
ENZALUTAMIDE.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 482.11 kB
Formato Adobe PDF
Visualizza/Apri
482.11 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/150443
Citazioni
  • ???jsp.display-item.citation.pmc??? 1020
  • Scopus 1982
  • ???jsp.display-item.citation.isi??? 2173
social impact